1. Introduction {#sec1}
===============

With increasing life expectancy, a growing number of patients with geriatric diseases including cancers have become issues of public health. Approximately more than 30% of patients with breast cancer are diagnosed at age over 70 years, and recent data suggest continuous increase of breast cancer incidence rates in women in their 60s (1.0% per year since 2004) and women older than 70 years (1.2% per year since 2005) \[[@B1]\]. Breast cancer is the most frequently diagnosed cancer in the world, and breast cancer alone is expected to occupy 30% of all cancers newly diagnosed in women in 2017 \[[@B2]\]. As the population of elders is expected to grow continuously, 20% of the population is estimated to be at age of 65 years or more by 2030 \[[@B3]\], which will lead to increased number of elderly patients with breast cancer. Despite anticipated increase of geriatric population with breast cancer, large prospective studies on older patients with breast cancer have been scarcely performed. Recent data on breast cancer statistics have shown an improvement of long-term mortality from breast cancer in all age groups from 1989 to 2012 largely due to progress in treatment and early detection through screening \[[@B1], [@B4]\], but the range of improvement is much smaller in elderly women aged over 70 years (1.5% per year) than that in young women aged 20 to 39 years (2.8% per year) \[[@B1]\]. The narrow range of reduction in mortality paradoxically suggests the lack of screening and the lack of treatment development for elderly breast cancer patients.

Comprehensive assessment on elderly patients, including life expectancy, comorbidities, and performance status, is always necessary to predict the benefit and risk of chemotherapy. While aging is one of reasons for undertreatment using surgery, radiation therapy, or chemotherapy, it is also a cause of increased use of endocrine therapy. Because chemotherapy, which usually accompanies unwanted adverse events, is not always the correct treatment option for patients with breast cancer, decision for initiation of anticancer therapy in geriatric patients with breast cancer might be a little easier if their histologic classifications are clear. Breast cancer expressing hormone receptors is one of candidates that can be managed without toxic chemotherapy. Breast cancer patients with positive expression of estrogen receptor (ER) or progesterone receptor (PgR) without expression of HER2 receptor are good candidates for endocrine therapy with fewer toxicities but equivalent treatment outcomes to chemotherapy. For physiologic reason of menopausal women, aromatase inhibitors (AIs) are often chosen as endocrine therapy agents in geriatric patients with breast cancer expressing hormone receptors. Here, we reviewed the hormone therapy as neoadjuvant, adjuvant, and palliative therapy in elderly patients with breast cancer.

2. Management of Geriatric Patients with Malignancies {#sec2}
=====================================================

Because treatment-related complications such as chemotherapy-induced toxicities have been thought to be associated with comorbidities in elderly cancer patients and risk of breast cancer-related mortality is regarded to be relatively reduced in elderly patients due to the elevated risk from other comorbidities-related deaths \[[@B5], [@B6]\], choice of aggressive treatment is not easy for elderly patients with breast cancer. Results from a previous Surveillance, Epidemiology, and End Results (SEER) registry data analysis assessing probabilities of death from breast cancer in the presence of competing risks showed patients with metastatic disease aged 70 years or older died from breast cancer, but causes of mortality in patients with other stages were attributed to comorbid diseases \[[@B7]\]. An observational study using four nationwide population registries in Denmark also reported that mild to moderate comorbidity assessed by Charlson Comorbidity Index affects mortality of breast cancer patients aged 50--79 years receiving chemotherapy \[[@B8]\]. An agreement exists that chronologic age itself should not be the only determinant in treatment of elderly patients with cancers. For the heterogeneity of the elderly in the same age in terms of physical, psychological, and cognitive function, as well as financial and social status, biological age taking consideration into individual health status and comorbid disease should be taken account in treatment decision. In order to address health status objectively, the International Society of Geriatric Oncology and the National Comprehensive Cancer Network recommend comprehensive geriatric assessment (CGA) before treatment decisions \[[@B9], [@B10]\]. CGA is a systematic procedure to assess multiple comorbidities and functional status of old patients through which geriatric problems not detected by routine oncology approach can be found. Several studies have reported that components of CGA, comorbid diseases, functional status, cognitive function, nutritional status, geriatric syndromes, and polypharmacy, are associated with survival and toxicity of chemotherapy in older patients with malignancies \[[@B11], [@B12]\]. In breast cancer, a study with patients older than 65-year harboring stage 1-3A has reported that the proportion of women who survived 10 years is significantly decreased as number of cancer-specific geriatric assessment (C-SGA) deficits is increased (linear trend *p* \< 0.0001) \[[@B11]\]. However, despite the proven benefit of CGA, this time-consuming tool limits its application to the busy clinical practice. Several screening tools such as Abbreviated CGA (aCGA), Geriatric 8 (G-8), Vulnerable Elders Survey (VES-13), Triage Risk Screening Tool (TRST 1+), and Groningen Fraility Index have been developed to overcome this disadvantage. Shorter and comprehensive geriatric evaluation is possible with these screening tools, but they should not replace CGA due to the lack of data that support the predictability of those screening tools for outcomes of CGA. A current guideline recommends the use of these screening tools only for the identification of patients who would benefit from CGA \[[@B10], [@B13]\].

3. Tumor Biology of Elderly Breast Cancer {#sec3}
=========================================

Biology and pathologic characteristics of breast cancer seem to change with increasing age. It is generally known that tumor biology of older patients with breast cancer shows less aggressive and indolent features, decreased frequency of axillary lymph node metastasis, vascular invasion, and lymphoplasmacytic stromal reaction \[[@B14]\]. Results from a retrospective study of 1758 women older than 70 years comparing tumor biology with younger counterparts showed higher expression of ER, PgR, Bcl2, and Muc1 but low expression of HER2, Ki76, p53, and EGFR in older group \[[@B15]\]. Moreover, the proportion of ER-positive breast cancer is increased with increasing age in cohort of patients over 65 years according to San Antonio Breast Cancer Database and SEER. It was revealed that 87% of patients aged 65 to 74 years showed ER positivity in their tumors, and the proportion of ER positivity was increased to 91% in patients older than 85 years \[[@B16]\]. Contrary to ER, HER2 expression is known to be less frequent in elderly patients with breast cancer; the proportion of cases with HER2 positive tumors is 4% in the cohort of over-60 years, while it is 9% in patients younger than 35 years \[[@B13], [@B17]\]. These results might mislead clinicians to conclude that endocrine therapy is the best choice in treatment of breast cancer of the elderly; however, it is known that the efficacy of hormone therapy is not correlated with age \[[@B18], [@B19]\].

On the other hand, some studies report aggressiveness of breast cancer in the elderly. A retrospective analysis from a single-institution showed greater likelihood of distant metastases in a subgroup of elderly patients aged over 70 years compared to that in the younger patients \[[@B20]\]. In addition, another study also reported that breast cancer was often detected at far advanced stage in the elderly; only 47% of patients with breast cancer aged over 75 years were found to have T1 tumors, while 70% of patients aged between 45 and 64 years were found to have T1 tumor, probably due to the lack of screening or delayed diagnosis \[[@B21]--[@B23]\].

Relevance of histologic classification of breast cancer to age has also been suggested by a retrospective analysis showing less aggressive features in the elderly in some cases. Certain histologic subtypes including infiltrating lobular carcinomas, mucinous carcinomas, and papillary carcinomas, which are slowly proliferating and low-grade tumors, have shown a gradual rise in incidence with increasing age \[[@B13], [@B14]\].

4. Endocrine Therapy in Elderly Breast Cancer Patients {#sec4}
======================================================

Because little data are available on endocrine therapy for elderly patients with breast cancer, these patients are generally treated as postmenopausal women. After menopause, adrenal glands and adipose tissue take over the role as major estrogen producing organs from ovaries. The fact that aromatase is an enzyme that acts on conversion of testosterone to estradiol and androstenedione to estrone, major source of estrogen in postmenopausal women \[[@B24]\], makes aromatase inhibitors (AIs) be preferred agents of hormone therapy for postmenopausal women with breast cancer. All currently used AIs are third generation represented by letrozole, anastrozole, and exemestane, exerting more potent efficacy comparing to first and second generations of AIs. Third generation AIs are classified as steroidal (type 1) and nonsteroidal (type 2) types according to their mechanisms of action ([Table 1](#tab1){ref-type="table"}). Type 1 AI, exemestane, inactivates aromatase by irreversibly binding to substrate\'s binding site of the enzyme. Type 2 AIs are letrozole and anastrozole which inhibit aromatase reversibly by binding to haem moiety of the enzyme \[[@B25], [@B26]\]. Agents used in endocrine therapy of elderly breast cancer patients are summarized in [Table 2](#tab2){ref-type="table"}.

4.1. Hormone Therapy in Neoadjuvant Treatment {#sec4.1}
---------------------------------------------

The efficacy of AIs in downstaging and reducing tumor volume before surgical interventions in postmenopausal women with breast cancer positive for hormone receptors who are potentially operable has been demonstrated in several randomized studies ([Table 3](#tab3){ref-type="table"}) \[[@B27]--[@B30]\]. Two prospective phase 2 studies compared the efficacy of neoadjuvant therapy by AIs to chemotherapy in postmenopausal women with hormone receptor-positive breast cancer. One study randomized ER-positive patients to receive anastrozole or exemestane for three months or doxorubicin and paclitaxel. Neoadjuvant endocrine therapy showed equivalent efficacy to chemotherapy in terms of overall objective response, pathologic complete response, and rates of breast-conserving surgery in ER-positive postmenopausal women \[[@B31]\]. Another study randomized postmenopausal or premenopausal patients with luminal breast cancer to receive chemotherapy (epirubicin plus cyclophosphamide followed by docetaxel) or hormone therapy with exemestane. No significant difference in clinical response rate was observed, suggesting equivalent efficacy of neoadjuvant endocrine therapy to chemotherapy \[[@B32]\].

4.2. Hormone Therapy as Adjuvant Treatment {#sec4.2}
------------------------------------------

The efficacy of AIs in adjuvant setting has been examined in several studies ([Table 4](#tab4){ref-type="table"}). Anastrozole Tamoxifen Alone and in Combination (ATAC) trial was a head-to-head trial comparing efficacy of anastrozole, an AI, with tamoxifen. More than 9000 postmenopausal patients were recruited, and 3125 were randomized to have anastrozole, 3116 to take tamoxifen, and 3125 to use a combination of both agents. The ATAC trial demonstrated that anastrozole was superior in terms of disease-free survival (DFS), distant metastases, and contralateral breast cancer compared to tamoxifen in postmenopausal women with early stage breast cancer \[[@B35], [@B26]--[@B34]\]. DFS at three years was 89.4% in the anastrozole group and 87.4% in the tamoxifen group (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.71--0.96, *p* = 0.013), and the superiority was maintained at 10 years (HR 0.91, 95% CI 0.83--0.99, *p* = 0.04). The favorable result of anastrozole over tamoxifen in DFS was more prominent in hormone receptor-positive postmenopausal breast cancer patients (HR 0.86, 95% CI 0.78--0.95, *p* = 0.003). After a median follow-up of 68 months, incidence of contralateral breast cancer (42% reduction, 95% CI 12--62, *p* = 0.01) and distant metastases (HR 0.86, 95% CI 0.74--0.99, *p* = 0.04) were significantly lower in the anastrozole group than in the tamoxifen group \[[@B35], [@B33], [@B34]\]. Furthermore, anastrozole appeared to be more beneficial for postmenopausal women aged more than 65 years in a subgroup analysis (HR 1.19, 95% CI 1.04--1.36) \[[@B33]\]. The combination therapy with tamoxifen and anastrozole had no advantage over tamoxifen monotherapy in DFS (HR 1.02, 95% CI 0.89--1.18, *p* = 0.8).

The Breast International Group (BIG) 1-98 is a randomized phase 3 trial comparing two different groups receiving letrozole first with two different groups receiving tamoxifen initially \[[@B37], [@B36]\]. The two letrozole initial groups were letrozole alone for 5 years and letrozole 2 years followed by tamoxifen for 3 years. The two tamoxifen first groups were tamoxifen monotherapy for 5 years and tamoxifen for 2 years followed by letrozole for 3 years. DFS was superior in the letrozole initial group to the tamoxifen first group (HR 0.81, 95% CI 0.70--0.93, *p* = 0.003) with a median follow-up of 25.8 months. Initial use of letrozole was also more beneficial in elderly patients aged more than 65 years in terms of DFS (HR 0.79, 95% CI 0.64--0.97, *p* = 0.02) \[[@B36]\]. With a longer follow-up, a median follow-up of 71 months, updated results showed no significant difference in DFS between letrozole monotherapy group and either sequential treatment groups (HR for tamoxifen and letrozole sequential group 1.05, 99% CI 0.84--1.32; HR for letrozole and tamoxifen sequential group 0.96, 99% CI 0.76--1.21) \[[@B37]\].

A letrozole extension study with large numbers of elderly breast cancer patients, the MA. 17 trial, showed benefit of extended therapy with letrozole after completion of adjuvant tamoxifen in postmenopausal women with hormone receptor-positive early stage breast cancer \[[@B38]\]. A total of 5,187 receptor-positive, postmenopausal early breast cancer patients who were disease-free after 5 years of treatment with tamoxifen were randomly assigned to receive either letrozole or placebo. Improved DFS was demonstrated in letrozole treated patients (HR, 0.58, 95% CI 0.45--0.76, *p* ≤ 0.001) at a median follow-up of 30 months. Patients were further subdivided into three age groups (\<60 years, 60 to 69 years, and ≥70 years) to see benefits of letrozole in elderly patients. Significantly different DFS favoring letrozole was shown only in patients younger than 60 years (HR 0.46, *p* ≤ 0.001). Because there was no interaction between age and treatment, the study suggested consideration of extended adjuvant therapy with letrozole after completing 5-year tamoxifen treatment in patients older than 70 years \[[@B39]\].

Two separate meta-analyses also demonstrated the superiority of AIs. Results from a meta-analysis of individual data on 31920 postmenopausal, ER-positive early stage breast cancer patients revealed the superiority of AIs to tamoxifen by showing reduced recurrence rate and decreased 10-year breast cancer mortality \[[@B40]\]. Another study by meta-analysis also proved efficacy of AIs with significantly lower recurrence rates compared to tamoxifen. There was no obvious heterogeneity between all age-subgroups. There was a 22% reduction in recurrence (SE 0.10) in patients aged over 70 years in the initial monotherapy with AIs group and a 19% reduction (SE 0.13) in those who used AIs after 2-3 years of tamoxifen comparing to tamoxifen monotherapy \[[@B41]\].

4.3. Hormone Therapy as Palliative Anticancer Treatment {#sec4.3}
-------------------------------------------------------

Considering great benefits with relatively fewer toxicities in association with hormone therapy, endocrine therapy is the most appropriate treatment modality for elderly breast patients. Patients who can benefit from endocrine therapy should always be accessed, and postmenopausal women with hormone receptor-positive metastatic or recurrent breast cancer are candidates for endocrine therapy. Clinical trials of endocrine therapy in palliative setting are summarized in [Table 5](#tab5){ref-type="table"}.

### 4.3.1. First-Line Endocrine Therapy in Postmenopausal Patients with Metastatic Breast Cancer {#sec4.3.1}

Several randomized phase 3 studies have demonstrated at least equivalence or the superiority of anastrozole, letrozole, and exemestane over tamoxifen in postmenopausal women with metastatic breast cancer ([Table 5](#tab5){ref-type="table"}) \[[@B42]--[@B46], [@B45], [@B47]\].

A series of recent studies have raised palbociclib (PD-0332991), a reversible and selective inhibitor of cyclin dependent kinases 4 and 6 (CDK 4/6), as one of agents recommendable for first-line and salvage endocrine therapy. CDK4 and CDK6, known to be activated by cyclin D, regulate G1-S transition of cell cycle by hyperphosphorylation of Rb \[[@B48]\]. Many experimental data have suggested that inhibition of cyclin D activity may lead to suppression of tumor growth and tumor cell death \[[@B49], [@B50]\]. The inhibitory effect of PD-0332991 was also shown in breast cancer cell lines, especially in luminal ER-positive human breast cancer cell lines including those with HER2 amplification. Meanwhile, nonluminal/basal breast cancer subtypes were found to be resistant to the inhibitory effect of PD-0332991 \[[@B51]\]. Based on those findings, clinical studies have investigated the efficacy of palbociclib in ER-positive postmenopausal advanced breast cancer patients \[[@B53], [@B52]\]. Results of a phase 2, open-label, randomized study investigating the efficacy of palbociclib in combination with letrozole compared to letrozole alone as first-line therapy in postmenopausal women with advanced ER-positive and HER2-negative breast cancer (PALOMA-1/TRIO-18) were reported about 2 years ago. The combination group showed two times of improvement in median progression-free survival (PFS) compared to the letrozole alone group (median PFS 20.2 versus 10.2 months, HR 0.488, 95% CI 0.319--0.748) \[[@B53]\].

Fulvestrant is a 17*β*-estradiol analog that inhibits estrogen signaling by downregulating the expression of ER protein \[[@B54]\]. Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) is a phase 2, randomized, open-label, multicenter trial investigating the efficacy of fulvestrant 500 mg compared to anastrozole 1 mg in postmenopausal ER-positive patients with advanced breast cancer who had no previous treatment. Results from this clinical trial showed equivalent efficacy of fulvestrant to anastrozole in terms of clinical benefit rate defined as the proportion of patients with objective response or stable disease for ≥24 weeks (72.5% versus 67%, OR 1.3, 95% CI 0.72--2.38, *p* = 0.386) and overall response (36.0% versus 35.5%, OR 1.02, 95% CI 0.56--1.87, *p* = 0.947). Time to progression (TTP) (median TTP 23.4 versus 13.1 months, HR 0.66, 95% CI 0.47--0.92, *p* = 0.01) and overall survival (OS) (median OS 54.1 versus 48.4 months, HR 0.7, *p* = 0.04) were shown to be improved in the fulvestrant group compared to the anastrozole group \[[@B55], [@B56], [@B57]\]. A prospective phase 3 clinical trial is currently undergone ([NCT01602380](http://www.clinicaltrial.co/ShowTrial/NCT01602380)).

### 4.3.2. Endocrine Therapy Beyond Progression to First-Line Hormone Treatment in Postmenopausal Women with Metastatic or Recurrent Breast Cancer {#sec4.3.2}

Resistance to hormone therapy in patients with receptor-positive breast cancer is not unusual. One of suggested resistance mechanisms to endocrine therapy is aberrant activation of phosphatidylinositol 3-kinase- (PI3k-) Akt-mammalian target of rapamycin (mTOR) signaling pathway \[[@B58]--[@B60]\]. Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study is a phase 3 randomized clinical trial that compares everolimus, an mTOR inhibitor, and exemestane versus exemestane and placebo in ER-positive postmenopausal patients with advanced breast cancer refractory to previous letrozole or anastrozole. After a median follow-up of 18 months, median PFS was shown to be significantly longer in the everolimus plus exemestane group than that of the placebo plus exemestane group (median PFS 7.8 versus 3.2 months, HR 0.45, 95% CI 0.38--0.54, *p* \< 0.0001) \[[@B61], [@B62]\]. Analysis on elderly patients aged 65 years or more was performed among patients enrolled in the BOLERO-2 study, and significantly improved PFS was consistently reported in those patients (HR in ≥65 years 0.59, 95% CI 0.43--0.80; HR in ≥70 years 0.45, 95% CI 0.30--0.68). Older patients treated by everolimus showed similar incidence of adverse events compared to younger patients, but they had more frequent incidence of on-treatment deaths (on-treatment deaths in those \<70 years of age, 1.3%; in those ≥70 years, 7.7% in exemestane plus everolimus group) \[[@B63]\].

A phase 3 study with advanced hormone receptor-positive, HER2 negative breast cancer patients who relapsed or progressed during previous hormone therapy was performed to compare the efficacy of palbociclib and fulvestrant versus placebo and fulvestrant. This study included both pre- and postmenopausal women. The combination therapy showed superior efficacy with longer median PFS (9.2 versus 3.8 months, HR 0.42, 95% CI 0.32--0.56, *p* \< 0.001). The majority of patients in this study were postmenopausal women (\>70%). HR for disease progression in patients older than 65 years was comparable to that in younger patients (HR in ≥65 years 0.35, 95% CI 0.19--0.62; HR in \<65 years 0.44, 95% CI 0.32--0.61, *p* = 0.48) in subgroup analysis \[[@B64]\].

5. Adverse Effects of Hormone Therapy {#sec5}
=====================================

Although AIs are relatively tolerable, adverse effects from their prolonged use should always be considered and managed adequately to improve compliance. Due to their different action of mechanisms, no proven estrogenic effects of AIs, spectrum of adverse effects of AIs is somewhat discriminated from that of selective estrogen receptor modulator (SERM), tamoxifen. Several clinical studies on those hormone agents have reported slightly better toxicity profiles of AIs.

5.1. Musculoskeletal Complication {#sec5.1}
---------------------------------

Musculoskeletal complication is one of discriminating adverse events attributing to the use of AIs from the use of SERM. The majority of clinical trials on AIs showed significantly increased incidence of musculoskeletal events in patients taking AIs comparing to those having tamoxifen or placebo \[[@B44], [@B34], [@B39], [@B65]\]. Contrary to the protective effect of tamoxifen on bone loss and bone mineral density \[[@B66]\], AIs are generally known to be associated with osteoporosis and bone fracture \[[@B67]\]. A systematic review of 11 randomized controlled trials (RCTs) on adverse bone outcomes in the elderly using AIs reported that fracture risk of AIs is 1.5 times higher than that of tamoxifen or placebo \[[@B68]\]. In previously conducted ATAC trial, significantly larger numbers of patients with anastrozole were reported to experience skeletal events such as arthralgia and fracture than those with tamoxifen \[[@B34], [@B68]\]. Data from toxicity analysis of letrozole in MA.17 trial showed patients with letrozole had significantly more frequent incidence of arthralgia than those with placebo in patients younger than 70 years \[[@B39]\]. The fracture rate was not shown to be significantly different between two groups, and this might be attributed to tamoxifen effect which had been used for 5 years before randomization to letrozole \[[@B68]\]. Considering adverse skeletal events attributing to AIs, all patients with AIs are recommended to take advice on exercise, calcium-vitamin D supplements, and bone mineral density (BMD) monitoring. If T-score is less than −2.0 or at least two risk factors for fracture are observed, bisphosphonate therapy should be considered. Patients with T-score more than −2.0 without accompanying risk factors are treated based on BMD loss during 1-2 years. Risk factors for fracture in patients with breast cancer include the use of AIs, T-score \< −1.5, age older than 65 years, BMI \< 20 kg/m^2^, family history of hip fracture, history of fragility fracture after age 50 years, prolonged corticosteroid use, and smoking \[[@B69]\]. A large quantity of data support bisphosphonate or a RANKL inhibitor, denosumab, therapy as appropriate antiabsorptive therapy to prevent osteoporosis in postmenopausal women having AIs.

Four independent studies on efficacy of zoledronic acid (4 mg i.v. q 6 months) and one study on denosumab (Hormone Ablation Bone Loss Trial in Breast Cancer; HALT-BC, 60 mg s.c. q 6 months) demonstrated their benefits in preventing bone loss \[[@B70]--[@B74]\]. More encouraging recent results from a study on adjuvant bisphosphonate therapy are antitumor effect and survival benefit of antiabsorptive therapeutic agent. A meta-analysis from EBCTCG reported that the use of adjuvant bisphosphonate in postmenopausal women reduced recurrence and mortality from breast cancer \[[@B75]\]. All results from these studies support the use of bisphosphonate and denosumab in postmenopausal women treated with AIs, but unwanted adverse events from using these antiabsorptive agents should be noted. Osteonecrosis, renal insufficiency, myalgia, arthralgia, and electrolyte imbalance including hypocalcemia are complications that should be considered before initiating adjuvant bisphosphonate therapy. Long-term risks of denosumab therapy have not been reported yet.

5.2. Endometrial Cancer {#sec5.2}
-----------------------

Avoidance of postmenopausal women with AIs from exposure to estrogen made favorable toxicity profile for them in terms of endometrial cancer, vaginal discharge, and bleeding. The ATAC study reported more frequent incidence of vaginal bleeding and discharge and endometrial cancer in patients having tamoxifen \[[@B34]\]. Five-year administration of tamoxifen before the use of letrozole resulted in equivalent frequency of vaginal bleeding between letrozole and placebo groups in MA.17 study \[[@B39]\]. A meta-analysis of RCTs comparing AIs with tamoxifen also reported reduced risk of AIs for endometrial cancer \[Odds ratio (OR) 0.34, 95% CI 0.22--0.53, *p* \< 0.001\] \[[@B76]\]. Another patient-level meta-analysis of 31920 postmenopausal women also showed lower incidence of endometrial cancer with AIs than tamoxifen (10-year incidence 0.4% versus 1.2%, relative risk 0.33, 95% CI 0.21--0.51). The decreased incidence of endometrial cancer with AIs was independent of age and lasted for years after finishing the endocrine therapy \[[@B40]\].

5.3. Vascular Events {#sec5.3}
--------------------

Due to the absence of estrogenic effect in AIs, incidence of vascular events including thromboembolic and cerebrovascular events is also expected to be decreased compared to that in patients taking tamoxifen. Results from safety analysis of ATAC trial showed reduced incidence of ischemic cerebrovascular (anastrozole versus tamoxifen 1.1% versus 2.3%, *p* \< 0.001), all venous thromboembolic (2.2% versus 3.8%, *p* \< 0.001), and deep venous thromboembolic events (1.1% versus 1.8%, *p* = 0.027), although no difference in frequency of ischemic cardiovascular events (2.8% versus 2.2%, *p* = 0.121) was observed \[[@B77]\]. Decreased incidence of thromboembolic events was consistently observed in the BIC 1-98 trial (letrozole versus tamoxifen 1.5% versus 3.5%, *p* \< 0.001). Cerebrovascular accident or transient ischemic accident (1.0% versus 1.0%, *p* = 0.91) and ischemic heart disease (1.4% versus 1.2%, *p* = 0.28) showed no significant difference in incidence between letrozole and tamoxifen groups in that study \[[@B36]\]. A meta-analysis of 30023 patients also showed coherent results in terms of adverse vascular events. This study reported no significant difference in the odds of cerebrovascular disease between the two groups (OR 1.01, 95% CI 0.81--1.26, *p* = 0.93); meanwhile it significantly increased odds in AIs users in terms of cardiovascular disease (OR 1.30, 95% CI 1.06--1.61, *p* = 0.01) and decreased odds in venous thrombosis in AIs users (OR 0.55, 95% CI 0.46--0.64, *p* \< 0.001) \[[@B76]\].

6. Adherence to Endocrine Therapy {#sec6}
=================================

Due to less severe toxicity profile of endocrine therapy compared to chemotherapy, it is usually expected that patients will adhere to endocrine therapy. However, results from the MA. 17 trial showed that the proportion of patients who discontinued treatment due to toxicities in the elderly aged over 60 years was similar between letrozole and placebo groups \[[@B39]\]. BIG 1-98 prospective trial showed that the proportions of treatment discontinuation were 38.4% in patients aged 75 years or more and 22.66% in those younger than 75 years without significant difference between letrozole and tamoxifen groups (*p* = 0.71) \[[@B78]\]. These data suggest that age itself other than toxicities might be one of major factors affecting the adherence to endocrine therapy. A systematic review, in which most studies focused on compliance to adjuvant endocrine therapy in patients with breast cancer, evaluating adherence to cancer treatment in elderly patients found that adherence rate varied from 52% to 100%. Factors for nonadherence were shown to vary across studies \[[@B79]\]. Another systematic review on adherence to medications also described various factors such as socioeconomic-related factors, healthcare team related factors, system related factors, condition-related factors, therapy-related factors, and patients-related factors as determinants of patients compliance \[[@B80]\]. As a matter of fact, several studies reported poor adherence and low use of adjuvant endocrine therapy in low-income breast cancer patients \[[@B81]--[@B83]\]. It seems that health status represented by presence of comorbidities in addition to chronological age is also an important contributing factor to adherence to endocrine therapy in stage 2 to 3 breast cancer patients. \[[@B84]\]. Duration of endocrine therapy is another factor for adherence. A study on endocrine therapy use in elderly breast cancer patients showed noncompliance with time from diagnosis \[[@B81]\]. Therefore, considering necessity of long-term adherence in endocrine therapy, not only age but also various circumstances that patients on treatment are facing should be taken into account to improve compliance, because improvement in compliance consequently can lead to better treatment outcomes.

7. Conclusion {#sec7}
=============

Despite prolongation of life expectancy and subsequent growing number of geriatric population with breast cancer, progress of studies on those patients, a considerable proportion in patients with breast cancer, is below expectations at present. In this review, we summarized representative studies on AIs used in postmenopausal women. We also tried to focus on studies which included subgroup analyses on elderly patients. However, because there are several problems in currently performed studies on geriatric breast cancer patients, limitation also exists in this study.

The lack of large prospective studies in which patients with breast cancer are consisted only with the elderly is one of rush assignments to be solved to provide appropriate guide in treatment of geriatric patients with breast cancer. Exploration on conditions where endocrine therapy can be the most appropriate treatment choice other than known histology subclassification could also be useful given that hormone therapy is a relatively easy remedy to apply to geriatric patients. Although endocrine therapy is usually regarded as treatment with less burden for risks compared to chemotherapy, AI-specific adverse events such as skeletal events should always be monitored by treatment providers. Various situations that decrease adherence to treatment in the elderly are also one of problems we should consider in their management to improve treatment outcomes. Further efforts are needed to find appropriated therapy in older breast cancer patients to prepare for the coming geriatric era in the near future.
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###### 

Classification of aromatase inhibitors.

                          1st generation      2nd generation   3rd generation
  ----------------------- ------------------- ---------------- ----------------
  Steroidal (type 1)                          Formestane       Exemestane
                                                               
  Nonsteroidal (type 2)   Aminoglutethimide   Fadrozole        Letrozole
  Anastrozole                                                  
  Vorozole                                                     

###### 

Endocrine therapy of the elderly with breast cancer.

  Hormone agent   Mechanism           Dose
  --------------- ------------------- ---------------------
  Letrozole       Reversible AIs      2.5 mg daily PO
  Anastrozole     Reversible AIs      1 mg daily PO
  Exemestane      Irreversible AI     25 mg daily PO
  Fulvestrant     SERD                500 mg IM q 28 days
  Everolimus      mTOR inhibitor      10 mg daily PO
  Palbociclib     CDK 4/6 inhibitor   125 mg daily PO

AI, aromatase inhibitor; SERD, selective estrogen receptor downregulator; mTOR, mammalian target of rapamycin; CDK, cyclin dependent kinase.

###### 

Clinical trials of neoadjuvant endocrine therapy in elderly patients with breast cancer.

  Study                          Design                                Number of patients   Treatment                                                                           Primary end point   Results                              *p*
  ------------------------------ ------------------------------------- -------------------- ----------------------------------------------------------------------------------- ------------------- ------------------------------------ ---------
  PROACT \[[@B27]\]              Phase 3, randomized, double-blind     451                  Anastrozole 1 mg versus tamoxifen 20 mg                                             OR                  39.5 versus 35.4%; odds ratio 1.24   0.29
  IMPACT \[[@B28]\]              Phase 3, randomized, double-blinded   330                  Anastrozole 1 mg versus tamoxifen 20 mg versus anastrozole 1 mg + tamoxifen 20 mg   OR                  37 versus 36 versus 39%               
  Z1031 \[[@B29]\]               Phase 2, randomized                   374                  Exemestane 25 mg versus letrozole 2.5 mg versus anastrozole 1 mg                    OR                  62.9 versus 74.8 versus 69.1%         
  Eiermann et al. \[[@B30]\]     Phase 3, randomized, double-blinded   337                  Letrozole 2.5 mg versus tamoxifen 20 mg                                             OR                  55% versus 36%                       \<0.001
  Semiglazov et al. \[[@B31]\]   Phase 2, randomized                   239                  Anastrozole 1 mg or exemestane 25 mg versus doxorubicin + paclitaxel                OR                  64.5 versus 63.6%                    \>0.5
  GEICAM/2006-03 \[[@B32]\]      Phase 2, randomized                   95                   Exemestane 25 mg versus EC-T                                                        OR                  48 versus 66%                        0.075

No, number; OR, objective response; EC-T, epirubicin and cyclophosphamide followed by docetaxel.

###### 

Clinical trials of adjuvant endocrine therapy in elderly patients with breast cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Design                              Number of patients   Treatment                                                                           Primary end point   Results                                  *p*
  --------------------- ----------------------------------- -------------------- ----------------------------------------------------------------------------------- ------------------- ---------------------------------------- ---------
  ATAC \[[@B35]\]       Phase 3, randomized                 9366                 Anastrozole 1 mg versus tamoxifen 20 mg versus anastrozole 1 mg + tamoxifen 20 mg   DFS                 A versus T; HR 0.91, 95% CI 0.83--0.99   0.04

  BIG 1-98 \[[@B37]\]   Phase 3, randomized, double-blind   8010                 T-L versus letrozole\                                                               DFS                 HR 1.05, 99% CI 0.84--1.32\               
                                                                                 L-T versus letrozole                                                                                    HR 0.96, 99% CI 0.76--1.21               

  MA. 17 \[[@B38]\]     Phase 3, randomized, double-blind   5187                 Tamoxifen-letrozole versus tamoxifen-placebo                                        DFS                 HR 0.58, 95% CI 0.45--0.76               \<0.001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

No, number; DFS, disease-free survival; A, anastrozole; T, tamoxifen; HR, hazard ratio; CI, confidence interval; L, letrozole.

###### 

Clinical trials of palliative endocrine therapy in elderly patients with breast cancer.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Design                                Number of patients   Treatment                                                            Primary end point   Results                           *p*
  ----------------------------- ------------------------------------- -------------------- -------------------------------------------------------------------- ------------------- --------------------------------- ----------
  *First line*                                                                                                                                                                                                         

  TARGET \[[@B42]\]             Phase 3, randomized, double-blind     668                  Anastrozole 1 mg versus tamoxifen 20 mg                              TTP\                8.2 versus 8.3 mths, HR 0.99\     0.941\
                                                                                                                                                                OR                  32.9 versus 32.6%                 0.787

  Nabholtz et al. \[[@B43]\]    Phase 3, randomized, double-blind     353                  Anastrozole 1 mg versus tamoxifen 20 mg                              TTP\                11.1 versus 5.6 moths HR, 1.44\   0.005
                                                                                                                                                                OR                  21 versus 17%                     

  Paridaens et al. \[[@B44]\]   Phase 3, randomized, open-label       371                  Exemestane 25 mg versus tamoxifen 20 mg                              PFS                 HR 0.84, 95% CI 0.67--1.05        0.121

  Mouridsen et al. \[[@B46]\]   Phase 3, randomized, double-blind     916                  Letrozole 2.5 mg versus tamoxifen 20 mg                              TTP                 9.4 versus 6.0 moths, HR 0.72     \<0.0001

  PALOMA-1/TRIO-18 \[[@B53]\]   Phase 2, open-label, randomized       165                  Letrozole 2.5 mg versus letrozole 2.5 mg + palbociclib 125 mg        PFS                 10.2 versus 20.2 mths, HR 0.488   ≤0.001

  FIRST \[[@B55]\]              Phase 2, open-label, randomized       205                  Fulvestrant 500 mg versus anastrozole 1 mg                           CBR                 72.5 versus 67%                   0.386

  *Second line*                                                                                                                                                                                                        

  BOLERO-2 \[[@B61]\]           Phase 3, randomized, double-blind     724                  Everolimus 10 mg + exemestane 25 mg versus exemestane 25 mg          PFS                 6.9 versus 2.8 mths, HR 0.43      \<0.001

  PALOMA3 \[[@B64]\]            Phase 3, randomized, double-blinded   521                  Palbociclib 125 mg + fulvestrant 500 mg versus. fulvestrant 500 mg   PFS                 9.2 versus 3.8 mths, HR 0.42      \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

No, number; TTP, time to progression; OR, objective response; mths, month; HR, hazard ratio; PFS, progression-free survival; CBR, clinical benefit rate (proportion of patients with objective response or stable disease for ≥24 weeks).
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